<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JBA</journal-id>
<journal-id journal-id-type="hwp">spjba</journal-id>
<journal-id journal-id-type="nlm-ta">J Biomater Appl</journal-id>
<journal-title>Journal of Biomaterials Applications</journal-title>
<issn pub-type="ppub">0885-3282</issn>
<issn pub-type="epub">1530-8022</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885328211415722</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885328211415722</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts <italic>in vitro</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kadow-Romacker</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0885328211415722">1</xref>
<xref ref-type="corresp" rid="corresp1-0885328211415722"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Greiner</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff2-0885328211415722">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schmidmaier</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff3-0885328211415722">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wildemann</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff1-0885328211415722">1</xref>
<xref ref-type="corresp" rid="corresp1-0885328211415722"/>
</contrib>
</contrib-group>
<aff id="aff1-0885328211415722"><label>1</label>Berlin–Brandenburg Center for Regenerative Therapies, Julius Wolff Institut, Charité – Universitätsmedizin Berlin, Berlin, Germany</aff>
<aff id="aff2-0885328211415722"><label>2</label>Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Berlin, Germany</aff>
<aff id="aff3-0885328211415722"><label>3</label>Department for Orthopedic and Trauma Surgery, University Clinic of Heidelberg, Heidelberg, Germany</aff>
<author-notes>
<corresp id="corresp1-0885328211415722">B Wildemann, Berlin–Brandenburg Center for Regenerative Therapies, Julius Wolff Institut, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Email: <email>britt.wildemann@charite.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<fpage>577</fpage>
<lpage>585</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The combination of a bone graft material with bisphosphonates (BPs) might be advantageous for an optimal balance of material resorption and stimulation of bone formation. This study investigated the effect of β-tricalcium phosphate (β-TCP) bone grafts coated with zoledronic acid (ZOL) on osteoblast-like cells and osteoclast-like cells (OLC). As a drug carrier, the polymer poly(D,L-lactide) was used and three different concentrations of ZOL were tested. β-TCP coated with ZOL stimulated the production of osteocalcin (OC), osteoprotegerin, and sRANKL in osteoblast-like cells. The polymer coating alone caused a significant increase in collagen type 1 and OC production. OLC viability was inhibited and the tartrate-resistant acidic phosphatase isoform-5b was significantly decreased after cultivation on polymer-coated β-TCP for 12 days. The three different concentrations of ZOL decreased cell viability and no TRAPiso-5b was detectable, indicating a strong reduction of the TRAPiso-5b after 12 days in culture. After 21 days in culture, only the higher ZOL concentrations significantly reduced cell viability and TRAPiso-5b. The results of this study show that coating of β-TCP with ZOL has stimulating effects on osteoblast-like cells. Additionally, an inhibition of osteoclasts was seen. The combination of this bone grafting material with BPs might, therefore, be effective in the treatment of large bone defects.</p>
</abstract>
<kwd-group>
<kwd>TCP</kwd>
<kwd>bisphosphonate</kwd>
<kwd>poly(D</kwd>
<kwd>L-lactide) coating</kwd>
<kwd>osteoblast-like cells</kwd>
<kwd>osteoclast-like cells</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0885328211415722" sec-type="intro"><title>Introduction</title>
<p>In the treatment of bone defects, autologous, allogenic, or alloplastic bone grafts are widely accepted. Autologous cancellous bone is considered to be the ‘golden standard’ grafting material because it provides an osteoconductive scaffold and contains growth factors for osteoinduction and progenitor cells for osteogenesis.<sup><xref ref-type="bibr" rid="bibr1-0885328211415722">1</xref></sup> However, retrieval of autologous bone involves a morbidity risk and its availability is also limited.<sup><xref ref-type="bibr" rid="bibr2-0885328211415722">2</xref>,<xref ref-type="bibr" rid="bibr3-0885328211415722">3</xref></sup> Synthetic bone grafts, e.g., hydroxyapatite or tricalcium phosphate (TCP) could be alternatives to autologous bone,<sup><xref ref-type="bibr" rid="bibr4-0885328211415722">4</xref>,<xref ref-type="bibr" rid="bibr5-0885328211415722">5</xref></sup> but they lack intrinsic properties such as osteoinductivity and osteogenesis.<sup><xref ref-type="bibr" rid="bibr1-0885328211415722">1</xref></sup>TCP grafts, as osteoconductive biomaterials,<sup><xref ref-type="bibr" rid="bibr6-0885328211415722">6</xref></sup> are frequently used for bone regeneration.<sup><xref ref-type="bibr" rid="bibr7-0885328211415722">7</xref></sup> In several <italic>in vivo</italic><sup><xref ref-type="bibr" rid="bibr8-0885328211415722">8</xref>,<xref ref-type="bibr" rid="bibr9-0885328211415722">9</xref></sup> and <italic>in vitro</italic><sup><xref ref-type="bibr" rid="bibr10-0885328211415722">10</xref>,<xref ref-type="bibr" rid="bibr11-0885328211415722">11</xref></sup> studies, the effect of β-TCP on bone regeneration was investigated. TCP can be completely resorbed by osteoclasts and is replaced by new bone tissue.<sup><xref ref-type="bibr" rid="bibr12-0885328211415722">12</xref></sup> The relationship between graft resorption and new bone formation is important for the effectiveness of a grafting material.</p>
<p>Bisphosphonates (BPs) are used clinically to inhibit osteoclast resorption in metabolic bone diseases and tumors.<sup><xref ref-type="bibr" rid="bibr13-0885328211415722">13</xref>,<xref ref-type="bibr" rid="bibr14-0885328211415722">14</xref></sup> They induce a positive bone balance<sup><xref ref-type="bibr" rid="bibr15-0885328211415722">15</xref></sup> and away from osteoclast resorption by affecting the mevalonate pathway.<sup><xref ref-type="bibr" rid="bibr16-0885328211415722">16</xref><xref ref-type="bibr" rid="bibr17-0885328211415722"/>–<xref ref-type="bibr" rid="bibr18-0885328211415722">18</xref></sup> Application of BPs has thus far been strictly systemic, resulting in high serum concentrations with possible side-effects such as osteomalcia, influenza-like symptoms, and BP associated osteonecrosis of the jawbone.<sup><xref ref-type="bibr" rid="bibr19-0885328211415722">19</xref></sup> Local BP application in animal models has proven to reduce bone resorption, thus preventing prosthetic implant loosening<sup><xref ref-type="bibr" rid="bibr20-0885328211415722">20</xref>,<xref ref-type="bibr" rid="bibr21-0885328211415722">21</xref></sup> and stimulating fracture healing.<sup><xref ref-type="bibr" rid="bibr22-0885328211415722">22</xref><xref ref-type="bibr" rid="bibr23-0885328211415722"/>–<xref ref-type="bibr" rid="bibr24-0885328211415722">24</xref></sup> Several <italic>in vitro</italic> studies analyzed the effect of BPs on specific cell types. BPs stimulate in a dose-dependent manner proliferation, differentiation, mineralization, gene expression, and osteoprotegerin (OPG) production of human osteoblasts.<sup><xref ref-type="bibr" rid="bibr25-0885328211415722">25</xref>,<xref ref-type="bibr" rid="bibr26-0885328211415722">26</xref></sup> Panzavolta et al.<sup><xref ref-type="bibr" rid="bibr27-0885328211415722">27</xref></sup> showed stimulating effects on osteoblasts from α-TCP combined with BPs (pamidronate and alendronate). Moreover, osteoclasts vitality was decreased when cultured in the presence of BPs.</p>
<p>The combination of a well-established biomaterial with a drug that stimulates bone formation and reduces material resorption might result in an innovative grafting material for the treatment of bone defects. This study aims to investigate the effect of β-TCP (ChronOS®) blocks coated with BP (ZOL; zoledronic acid) on primary human osteoblast-like cells (POB) and osteoclast-like cells (OLC). The ZOL was incorporated into a poly(D,L-lactide) (PDLLA) suspension in three different concentrations and the β-TCP blocks were soaked with this solution. Cell viability, differentiation, and protein synthesis of POB and OLC were determined after incubation with the material.</p>
</sec>
<sec id="sec2-0885328211415722" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0885328211415722"><title>Sterilization and coating of β-TCP</title>
<p>The β-TCP blocks (ChronOS®, Synthes, USA) had a porosity of 60–80%, a pore size 100–500 µm, a diameter 14 mm and a thickness 5 mm.</p>
<p>They were sterilized by washing with 70% ethanol (Sigma, Germany) for 2 h followed by washing with phosphate buffered saline for five times (Biochrom AG, Germany) and drying over night under sterile conditions. Performing a limulus amebocyte lysate test (Pyrogent plus, Lonza, Germany) on some samples, no endotoxin contamination was detected.</p>
<p>ZOL (Novartis, Switzerland) was incorporated in a PDLLA coating that served as a drug-delivery system. The coating was performed according to established methods; the TCP was dipped two times in the PDLLA (molecular weight around 30,000 Da, Boehringer Ingelheim, Germany) and dissolved in ethyl acetate (Sigma, Germany).<sup><xref ref-type="bibr" rid="bibr28-0885328211415722">28</xref></sup> After coating, the TCP blocks were dried under the laminar flow over night. Three different concentrations of ZOL were used: 0.4%; 1.2%, and 2% (w/w PDLLA). Furthermore, TCP coated with PDLLA (without ZOL) and uncoated β-TCP served as controls.</p>
</sec>
<sec id="sec4-0885328211415722"><title>Cell culture</title>
<p>POB were isolated from human proximal tibia bone after reconstructive surgery (total knee arthroplasty) of three different donors. Written informed consent was obtained from all donors. The isolation of the cells followed established protocols.<sup><xref ref-type="bibr" rid="bibr29-0885328211415722">29</xref></sup> POBs were seeded with a density of 3 × 10<sup>4</sup> dissolved in MEM-E/Ham’s F-12 with 10% heat-inactivated fetal calf serum (FCS), β-glycerol phosphate, L-ascorbic acid, and 1% penicillin/streptomycin. Osteoblasts were cultivated for 12 days under standard conditions (all cell culture supplements by Biochrom AG, Germany). Prior to the experiments, the phenotype of the cells was characterized by morphological parameters. After cultivation of the cells for 28 days, bone-specific alkaline phosphatase (ALP) was determined by staining of formaldehyde fixed cells (Sigma, Germany) with 3,3′-dimethoxy-biphenyl-4,4′-bis-diazonium dichloride (Chroma Gesellschaft, Germany) and Naphtol-AS-MX-Phosphat (Sigma, Germany) in dimethylformamide (99.9%) buffer (Sigma, Germany). The matrix mineralization was visualized by the use of von Kossa staining (3% silver nitrate and 5% sodium thiosilfate (Merck, Germany). Exemplary pictures are shown in <xref ref-type="fig" rid="fig1-0885328211415722">Figure 1</xref>.
<fig id="fig1-0885328211415722" position="float"><label>Figure 1.</label><caption><p>Characterization of ostoblasts-like cells: (a) ALP staining and (b) von Kossa staining (mineralized matrix).</p></caption><graphic xlink:href="10.1177_0885328211415722-fig1.tif"/>
</fig></p>
<p>For cultivation of primary OLC, monocytes (MCs) were isolated from buffy coats of three different donors. Written informed consent was obtained from all donors. According to an established protocol,<sup><xref ref-type="bibr" rid="bibr30-0885328211415722">30</xref></sup> MCs were separated by density gradient centrifugation (Histopaque, Sigma, Germany). Finally, the MCs were selected by CD14+ magnetic-activated cell sorting (by Miltenyi, GE). The MCs were cultured with alpha-MEM plus 10% FCS and 1% penicillin/streptomycin (Biochrom AG, Germany). Receptor activator of nuclear factor-κB ligand (RANKL) (20 ng/mL) (Peprotech Inc., USA) and macrophage colony-stimulating factor (5 ng/mL) (Sigma, Germany) was added to stimulate fusion to multinuclear OLC. The effect on the fusion of MCs and survival of OLC was investigated at two time points: after 12 or 21 days.</p>
<p>The isolated cells were seeded directly onto the β-TCP blocks with a density of 3 × 10<sup>4</sup> (POB) or 1 × 10<sup>6</sup> (MC) in 100 µL media for cell adherence and a pre-incubation period for 1 h was performed. Afterward, 1 mL of culture media was added to each well.</p>
</sec>
<sec id="sec5-0885328211415722"><title>Cell vitality</title>
<p>After incubation of POB and OLC on coated or uncoated β-TCP, the vitality of the cells was determined with a non-toxic alamarBlue assay (Biozol, Germany). Therefore, β-TCP blocks were transferred to new culture plates to ensure that only cells on the TCP were analyzed. The assay is based on the mitochondrial metabolism of vital cells, whereby a water-soluble blue colorant will be reduced to a red colorant which can be measured photometrical with a microplate reader at 570/595 nm (Biorad, Germany). The procedure followed the instructions of the manufacturer.</p>
</sec>
<sec id="sec6-0885328211415722"><title>ALP of POB</title>
<p>ALP is an early marker of osteoblast differentiation and activity.<sup><xref ref-type="bibr" rid="bibr31-0885328211415722">31</xref></sup> As described for the cell-vitality assay, β-TCP blocks were transferred to new culture plates and incubated with ALP substrate solution (1.3 mg of 4-nitrophenyl phosphate disodium salt hexahydrate in 1 mL of 0.1M AP-Puffer; pH 10.5, Sigma, Germany) for 30 min at 37°C. ALP activity of POB was measured by the color change from white to yellow photometricly at 405 nm (Biorad, Germany). The results were normalized to the cell vitality.</p>
</sec>
<sec id="sec7-0885328211415722"><title>Determination of total protein</title>
<p>Bradford™ assay was used to determine the amount of total protein (Coomassie blue, Pierce, Germany). Absorption was measured at 595 nm (Biorad, Germany) according to the instructions of the manufacturer.</p>
</sec>
<sec id="sec8-0885328211415722"><title>Enzyme-linked immuno assays</title>
<p>Enzyme-linked immuno assays (ELISAs) were performed to determine changes in the synthesis of specific proteins produced by osteoblasts and osteoclasts.</p>
<p>POB: Collagen type 1 (COL-1); osteocalcin (OC); (Tecomedical, Germany); OPG (Tecomedical, Germany); soluble receptor activator of nuclear factor (NF)-kB Ligand (sRANKL) (Tecomedical, Germany); OLC: TRAPiso-5b (Tecomedical, Germany).</p>
<p>All procedures followed the instructions of the manufacturers and the results were correlated to total protein.</p>
</sec>
<sec id="sec9-0885328211415722"><title>Compression test</title>
<p>To measure compressive strength of coated and uncoated β-TCP, compression tests with a material testing machine (Zwick, Germany) were performed. The magnitude of elastic modulus (E-module) was correlated to the resistance of the material against deformation. Forces of <italic>F</italic><sub>max</sub> = 200–600 N and elasticity modulus of 100–500 MPa (E-module) were applied and E-module and the actual forces which resulted in material failure were documented. Ten uncoated TCP specimens and 10 TCP coated specimens with PDLLA were analyzed at room temperature (~21°C).</p>
</sec>
<sec id="sec10-0885328211415722"><title>Statistical analysis</title>
<p>Cells from three different donors were used for independent experiments and the experiments were performed in triplicate per donor (<italic>n</italic> = 9). Statistics were performed with the Kruskal–Wallis test followed by Mann–Whitney test and Bonferroni–Holm correction for multiple comparisons. The box plots show the median, the 25–75% percentile, and the min–max. Statistical differences were defined at a 95% confidence level. Statistical comparison of data was conducted using SPSS (release 14.0; SPSS Inc., USA).</p>
</sec>
</sec>
<sec id="sec11-0885328211415722" sec-type="results"><title>Results</title>
<sec id="sec12-0885328211415722"><title>Osteoblast-like cells (POB)</title>
<p>No significant effect on the POB cell vitality and total protein content was seen after cultivation on β-TCP blocks with and without ZOL (<xref ref-type="table" rid="table1-0885328211415722">Table 1</xref>).
<table-wrap id="table1-0885328211415722" position="float"><label>Table 1.</label><caption><p>Parameters of osteoblasts and osteoclasts.</p></caption>
<graphic alternate-form-of="table1-0885328211415722" xlink:href="10.1177_0885328211415722-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Control</th>
<th>PDLLA</th>
<th>0.4% ZOL</th>
<th>1.2% ZOL</th>
<th>2% ZOL</th></tr></thead>
<tbody align="left">
<tr>
<td>Cell count Osteoblasts</td>
<td>100.00 (98.08–115.08)</td>
<td>111.88 (95.69–117.14)</td>
<td>105.33 (94.73–194.83)</td>
<td>82.86 (75.61–106.31)</td>
<td>90.00 (71.67–97.12)</td></tr>
<tr>
<td>ALP Osteoblasts</td>
<td>100.00 (96.13–106.25)</td>
<td>110.09 (82.21–119.89)</td>
<td>99.69 (80.23–110.20)</td>
<td>112.11 (71.38–132.18)</td>
<td>111.77 (99.46–125.55)</td></tr>
<tr>
<td>Protein Osteoblasts</td>
<td>100.00 (98.88–101.80]</td>
<td>90.67 (86.23–92.16)</td>
<td>89.24 (84.35–96.85)</td>
<td>98.39 (85.66–90.48)</td>
<td>94.41 (91.87–97.12)</td></tr>
<tr>
<td>OPG Osteoblasts</td>
<td>100.00 (93.13–103.35)</td>
<td>161.13<sup>*</sup> (116.85–174.49)</td>
<td>115.18<sup>**</sup> (101.08–126.64)</td>
<td>109.94<sup>***</sup> (106.71–118.15)</td>
<td>128.54<sup>****</sup> (114.23–143.88)</td></tr>
<tr>
<td>sRANKL Osteoblasts</td>
<td>100.00 (99.31–114.75)</td>
<td>99.56 (83.07–122.41)</td>
<td>127.46 (105.48–152.15)</td>
<td>167.14<sup>#</sup> (120.34–247.15)</td>
<td>175.64<sup>##</sup> (125.49–208.51)</td></tr>
<tr>
<td>Protein Osteoclasts (12 days)</td>
<td>100.00 (99.24–100.79)</td>
<td>99.97 (99.21–103.96]</td>
<td>98.22 (95.48–99.98)</td>
<td>99.27 (98.06–100.00)</td>
<td>101.03 (99.70–101.17)</td></tr>
<tr>
<td>Protein Osteoclasts (21 days)</td>
<td>100.00 (94.77–108.18)</td>
<td>107.58 (95.34–112.43)</td>
<td>116.79 (96.35–122.22)</td>
<td>102.92 (98.36–110.90)</td>
<td>100.00 (100.76–117.74)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0885328211415722"><p>Notes: Values are given as medians with 25–75 percentiles. OPG: *<italic>p</italic> = 0.001, **<italic>p</italic> = 0.027, ***<italic>p</italic> = 0.007, ****<italic>p</italic> = 0.003; sRANKL: <sup>#</sup><italic>p</italic> = 0.009, <sup>##</sup><italic>p</italic> = 0.016.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The quantity of COL-1 and OC was significantly increased after cultivation with the PDLLA coated β-TCP compared to uncoated control (<xref ref-type="fig" rid="fig2-0885328211415722">Figure 2(a)</xref> and (<xref ref-type="fig" rid="fig2-0885328211415722">b</xref>)). A significantly higher OC concentration was detected in the groups with the higher ZOL concentrations (1.2% and 2%) (<xref ref-type="fig" rid="fig2-0885328211415722">Figure 2(b)</xref>). In the PDLLA and all ZOL groups, OPG was enhanced significantly compared to control (<xref ref-type="table" rid="table1-0885328211415722">Table 1</xref>). Also, sRANKL was significantly increased in groups with 1.2% and 2% ZOL. No changes in the production of ALP by POBs after cultivation with the different ZOL concentrations or PDLLA could be determined (<xref ref-type="table" rid="table1-0885328211415722">Table 1</xref>).
<fig id="fig2-0885328211415722" position="float"><label>Figure 2.</label><caption><p>(a) Production of collagen-I (COL-I) by osteoblasts after cultivation on β-TCP, coated with ZOL. Coating of β-TCP with PDLLA leads to significantly more COL-1 synthesis by osteoblasts (<italic>p</italic>* <italic>=</italic> 0.001). (b) Significantly increased osteocalcin (OC) production by osteoblasts cultured on PDLLA and ZOL (1.2% and 2%) coated β-TCP was measured in cell culture supernatant after 12 days (<italic>p</italic>* = 0.00004 (PDLLA); 0.00028 (1.2% ZOL<italic>)</italic>; 0.00004 (2% ZOL)<italic>)</italic>. No changes were determined in the group with 0.4% ZOL compared to uncoated control. <italic>n</italic> = 9.</p></caption><graphic xlink:href="10.1177_0885328211415722-fig2.tif"/>
</fig></p>
</sec>
<sec id="sec13-0885328211415722"><title>Osteoclast-like cells</title>
<p>The influence of β-TCP coated with ZOL on the fusion of MCs to OLC and the long-term survival of the cells was investigated after 12 and 21 days of cultivation. A significant inhibition of the cell vitality was detected after cultivation with PDLLA and all ZOL concentrations for 12 days, compared to uncoated controls (<xref ref-type="fig" rid="fig3-0885328211415722">Figure 3(a)</xref>). After cultivation for 21 days, a reduction in cell vitality was detected for the 1.2% and 2% ZOL coated β-TCP. Results showed no influence of the PDLLA and the 0.4% ZOL group on the vitality (<xref ref-type="fig" rid="fig3-0885328211415722">Figure 3(b)</xref>). The TRAPiso-5b synthesis also showed different results regarding the cultivation period. For the shorter cultivation period (12 days), TRAPiso-5b was significantly reduced in the PDLLA group in comparison to the control. Moreover, in all ZOL groups, no TRAPiso-5b was measured and values were under the detection limit of the assay (<xref ref-type="fig" rid="fig3-0885328211415722">Figure 3(c)</xref>). The long-term cultivation (21 days) showed a significant decrease in TRAPiso-5b synthesis only in the 1.2% and 2.0% ZOL groups (<xref ref-type="fig" rid="fig3-0885328211415722">Figure 3(d)</xref>). There were no significant changes in the amount of TRAPiso-5b in the PDLLA-group.
<fig id="fig3-0885328211415722" position="float"><label>Figure 3.</label><caption><p>(a) Cell vitality of osteoclasts was significantly inhibited after a shorter cultivation time (12 days) in all coated groups; <italic>p</italic>* = 0.002 (PDLLA); 0.006 (0.4%); 0.014 (1.2%); 0.019 (2%). (b) At the longer culture time point (21 days), vitality of mature osteoclasts was significantly decreased after incubation with 1.2% and 2% ZOL (<italic>p</italic>*= 0.016; 0.00004). (c) Decreased values of TRAPiso-5b were measured after cultivation of osteoclasts on ZOL coated ChronOS® for 12 days. The values for the ZOL groups were below the lowest standard of the ELISA kit. Statistically significant decrease in TRAPiso-5b was measured in the PDLLA group compared to control (<italic>p</italic>* = 0.004). (d) Significantly less TRAPiso-5b was detected at the longer culture time point (21 days) after incubation with 1.2% and 2% ZOL (<italic>p</italic>*= 0.011; 0.002). <italic>n</italic> = 9.</p></caption><graphic xlink:href="10.1177_0885328211415722-fig3.tif"/>
</fig></p>
</sec>
<sec id="sec14-0885328211415722"><title>Compression test</title>
<p>No significant differences between coated and uncoated β-TCP were measured for the compressive strength. The coating with PDLLA did not influence the biomechanical properties of the β-TCP (<xref ref-type="fig" rid="fig4-0885328211415722">Figure 4</xref>).
<fig id="fig4-0885328211415722" position="float"><label>Figure 4.</label><caption><p>Compressive test: no significant differences in the E-module of the β-TCP was detected before (control) and after coating with PDLLA.</p></caption><graphic xlink:href="10.1177_0885328211415722-fig4.tif"/>
</fig></p>
</sec>
</sec>
<sec id="sec15-0885328211415722" sec-type="discussion"><title>Discussion</title>
<p>For the treatment of bone defects, synthetic bone grafts are increasingly used as alternatives to autologous bone grafts. However, in comparison to autologous bone, they have no or low osteogenic or osteoinductive properties.<sup><xref ref-type="bibr" rid="bibr1-0885328211415722">1</xref></sup> The optimization of different synthetic grafts (e.g., TCP; collagen sponge; hydroxyapatite) with bioactive substances (e.g., growth factors, BPs) has been previously performed.<sup><xref ref-type="bibr" rid="bibr32-0885328211415722">32</xref>,<xref ref-type="bibr" rid="bibr33-0885328211415722">33</xref></sup> Several studies showed positive effects on bone regeneration using different biomaterials in combination with BPs.<sup><xref ref-type="bibr" rid="bibr34-0885328211415722">34</xref><xref ref-type="bibr" rid="bibr35-0885328211415722"/><xref ref-type="bibr" rid="bibr36-0885328211415722"/>–<xref ref-type="bibr" rid="bibr37-0885328211415722">37</xref></sup> Recent studies described the preparation of biomaterials directly mixed with BPs.<sup><xref ref-type="bibr" rid="bibr27-0885328211415722">27</xref>,<xref ref-type="bibr" rid="bibr38-0885328211415722">38</xref><xref ref-type="bibr" rid="bibr39-0885328211415722"/>–<xref ref-type="bibr" rid="bibr40-0885328211415722">40</xref></sup> The release of ZOL out of a PDLLA coating of titanium wires revealed <italic>in vitro</italic> a stimulation of osteoblasts and an inhibition of OLC and <italic>in vivo</italic> an accelerated fracture healing.<sup><xref ref-type="bibr" rid="bibr24-0885328211415722">24</xref>,<xref ref-type="bibr" rid="bibr41-0885328211415722">41,44</xref></sup> PDLLA as a drug carrier for different factors was investigated in several <italic>in vitro</italic> and <italic>in vivo</italic> studies. The incorporated substances are released in a sustained manner after an initial peak (for review, see Schmidmaier et al.<sup><xref ref-type="bibr" rid="bibr42-0885328211415722">42</xref></sup>). Based on these findings, the objective of this study was to establish a combination of commercially available and clinically used β-TCP with the BP ZOL, released out of PDLLA coating. <italic>In vitro</italic> experiments with POB and OCL were performed to investigate the dose-dependent effect of ZOL on cell metabolism. In addition, β-TCP coated with PDLLA (without ZOL) and uncoated β-TCP (control) cultured with POB and OLC were investigated.</p>
<p>Cultivation of POB on PDLLA coated β-TCP significantly increased the production of COL-1, OC, and OPG compared to the control. All ZOL concentration resulted in a significantly enhanced OPG production. Only the higher ZOL concentrations (1.2% and 2%) increased the OC and sRANKL synthesis. POB vitality, total protein expression, and ALP activity were not influenced by PDLLA or any ZOL concentrations.</p>
<p>A time-dependent effect of the ZOL coated β-TCP on OLC was seen. The shorter incubation period resulted in a significant decrease in their cell vitality and TRAPiso-5b synthesis in all investigated ZOL groups and in the PDLLA group compared to the control. A longer cultivation period revealed only inhibiting effects on the OCL cultured with higher ZOL concentrations.</p>
<p>In this study, the polymer (PDLLA) alone had a stimulatory effect on POB. This positive effect from the PDLLA was also demonstrated in previous <italic>in vivo</italic> studies investigating rat fracture healing.<sup><xref ref-type="bibr" rid="bibr43-0885328211415722">43</xref></sup> This indicates that the polymer is a suitable carrier for drug delivery, having positive effects on the cells. The reason for this effect, however, is unclear and further studies are needed. However, it seems as if direct contact between the cells and the PDLLA is important for the stimulating effect. Culturing cells in a non-contact manner with PDLLA coated titanium showed no effect on the osteoblast-like cells.<sup><xref ref-type="bibr" rid="bibr29-0885328211415722">29</xref>,<xref ref-type="bibr" rid="bibr44-0885328211415722">44</xref>,<xref ref-type="bibr" rid="bibr45-0885328211415722">45</xref></sup></p>
<p>Previous <italic>in vivo</italic><sup><xref ref-type="bibr" rid="bibr22-0885328211415722">22</xref>,<xref ref-type="bibr" rid="bibr23-0885328211415722">23</xref>,<xref ref-type="bibr" rid="bibr34-0885328211415722">34</xref>,<xref ref-type="bibr" rid="bibr46-0885328211415722">46</xref>,<xref ref-type="bibr" rid="bibr47-0885328211415722">47</xref></sup> and <italic>in vitro</italic><sup><xref ref-type="bibr" rid="bibr26-0885328211415722">26</xref>,<xref ref-type="bibr" rid="bibr27-0885328211415722">27</xref>,<xref ref-type="bibr" rid="bibr44-0885328211415722">44</xref>,<xref ref-type="bibr" rid="bibr48-0885328211415722">48</xref>,<xref ref-type="bibr" rid="bibr49-0885328211415722">49</xref></sup> studies demonstrated stimulatory effects of BPs on osteoblasts and bone regeneration and formation. Our results showed only an increased OC production by BPs. Recent studies have shown inhibitory effects of ZOL on osteoblastic COL-1 production and osteoblastic cell proliferation using different concentrations.<sup><xref ref-type="bibr" rid="bibr50-0885328211415722">50</xref>,<xref ref-type="bibr" rid="bibr51-0885328211415722">51</xref></sup> In accordance with other studies, an inhibition of OLC was seen in the ZOL groups.<sup><xref ref-type="bibr" rid="bibr27-0885328211415722">27</xref>,<xref ref-type="bibr" rid="bibr44-0885328211415722">44</xref></sup> Faucheux et al.<sup><xref ref-type="bibr" rid="bibr39-0885328211415722">39</xref></sup> previously showed inhibition of osteoclastic resorption activity of rabbit bone cells after cultivation on a calcium phosphate biomaterial and controlled release of zoledronic (ZOL) acid.</p>
<p>The inhibitory effect on day 12 might be explained by the initial release of the BP from the coating. The early inhibition of osteoclasts is beneficial to inhibit scaffold resorption in the early phase of graft incorporation. The inhibitory effect, however, must be reversible at the later time point to allow the degradation of the material and ensure a remodeling of the graft. In this study, results from the longer cultivation time point (21 days) showed less inhibitory effects on the OLC regarding TRAPiso-5b synthesis and cell vitality. Therefore, releasing BPs from the coating might be more beneficial compared to other methods where the substance is incorporated into a scaffold by binding to hydroxyapatite crystals and will be released mainly by scaffold degradation.<sup><xref ref-type="bibr" rid="bibr27-0885328211415722">27</xref>,<xref ref-type="bibr" rid="bibr33-0885328211415722">33</xref>,<xref ref-type="bibr" rid="bibr52-0885328211415722">52</xref></sup></p>
<p>The OPG/RANKL system is important for the cross-talk of osteoblast-like cells and osteoclast-like cells.<sup><xref ref-type="bibr" rid="bibr53-0885328211415722">53</xref></sup> Culturing osteoblast-like cells on ZOL coated TCP resulted in an increased production of OPG, a decoy receptor for RANKL. Binding of OPG to RANKL might block the RANKL activity and therefore inhibit osteoclastogenesis. A previous study showed a significant RANKL reduction after cultivation of osteoblast-like cells with ZOL coated titanium wires.<sup><xref ref-type="bibr" rid="bibr44-0885328211415722">44</xref></sup> This study, however, showed the opposite effect with an enhanced sRANKL production at higher ZOL concentrations. This increase is in accordance with a recently published study by Koch et al.<sup><xref ref-type="bibr" rid="bibr54-0885328211415722">54</xref></sup> showing a dramatic increase of RANKL expression and a milder increase of OPG expression after stimulation of osteoblast-like cells with ZOL. To get functional information on the cross-talk of osteoblast-like cells and osteoclast-like cells, however, a co-culture of both cells must be performed.</p>
<p>No differences in the mechanical properties of commercially available β-TCP with and without coating were measured. Panzavolta et al.<sup><xref ref-type="bibr" rid="bibr27-0885328211415722">27</xref></sup> found that BPs reduced the compressive strength of calcium phosphate bone cements. This decrease can be explained by the change in the material properties due to the incorporation of alendronate or pamidronate in a cement composition (α-TCP) in the liquid phase.</p>
<p>In this study, commercial β-TCP blocks coated with ZOL were investigated in cell culture experiments with human osteoblast-like cells and osteoclast-like cells. A slight stimulating effect on osteoblast-like cells and a time dependent and reversible inhibition of osteoclast activity could be demonstrated. The mechanical properties of the TCP were unaffected. The optimization of clinically established materials with biologically active substances might be beneficial for the successful treatment of bony defects. For more information about the efficiency of β-TCP coated with BPs in bone healing, <italic>in vivo</italic> studies should follow.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank Dipl.-Ing. Alexander Schill for measuring the compressive strength of β-TCP and Claudia Schaar for analyzing TRAPiso-5b within the framework of a student research project. We thank Dr Milvia Lepre (Synthes, Switzerland) for providing the TCP-scaffolds.</p></ack>
<sec id="sec16-0885328211415722"><title>Funding</title>
<p>This study was partially funded by the Deutsche Forschungsgemeinschaft (DFG, SFB 760) and the Bundesministerium für Bildung und Forschung (BMBF, BCRT).</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0885328211415722"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannoudis</surname><given-names>PV</given-names></name><name><surname>Dinopoulos</surname><given-names>H</given-names></name><name><surname>Tsiridis</surname><given-names>E</given-names></name></person-group>. <article-title>Bone substitutes: An update</article-title>. <source>Injury</source> <year>2005</year>; <volume>36S</volume>: <fpage>S20</fpage>–<lpage>S27</lpage>.</citation></ref>
<ref id="bibr2-0885328211415722"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurz</surname><given-names>LT</given-names></name><name><surname>Garfin</surname><given-names>SR</given-names></name><name><surname>Booth</surname><given-names>RE</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Harvesting autogenous iliac bone grafts. A review of complications and techniques</article-title>. <source>Spine</source> <year>1989</year>; <volume>14</volume>(<issue>12</issue>): <fpage>1324</fpage>–<lpage>1331</lpage>.</citation></ref>
<ref id="bibr3-0885328211415722"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>HS</given-names></name><name><surname>Grewal</surname><given-names>HS</given-names></name><name><surname>Parvataneni</surname><given-names>H</given-names></name></person-group>. <article-title>Bone grafting for spinal fusion</article-title>. <source>Orthop Clin North Am</source> <year>1999</year>; <volume>30</volume>(<issue>4</issue>): <fpage>685</fpage>–<lpage>698</lpage>.</citation></ref>
<ref id="bibr4-0885328211415722"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erbe</surname><given-names>EM</given-names></name><name><surname>Marx</surname><given-names>JG</given-names></name><name><surname>Clineff</surname><given-names>TD</given-names></name><name><surname>Bellincampi</surname><given-names>LD</given-names></name></person-group>. <article-title>Potential of an ultraporous beta-tricalcium phosphate synthetic cancellous bone void filler and bone marrow aspirate composite graft</article-title>. <source>Eur Spine J</source> <year>2001</year>; <volume>10</volume>(<issue>2</issue>): <fpage>S141</fpage>–<lpage>S146</lpage>.</citation></ref>
<ref id="bibr5-0885328211415722"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeGeros</surname><given-names>RZ</given-names></name></person-group>. <article-title>Properties of osteoconductive biomaterials: Calcium phosphates</article-title>. <source>Clin Orthop Relat Res</source> <year>2002</year>; <volume>395</volume>: <fpage>81</fpage>–<lpage>98</lpage>.</citation></ref>
<ref id="bibr6-0885328211415722"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steffen</surname><given-names>T</given-names></name><name><surname>Stoll</surname><given-names>T</given-names></name><name><surname>Arvinte</surname><given-names>T</given-names></name><name><surname>Schenk</surname><given-names>RK</given-names></name></person-group>. <article-title>Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery</article-title>. <source>Eur Spine J</source> <year>2001</year>; <volume>10</volume>(<issue>2</issue>): <fpage>S132</fpage>–<lpage>S140</lpage>.</citation></ref>
<ref id="bibr7-0885328211415722"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keating</surname><given-names>JF</given-names></name><name><surname>McQueen</surname><given-names>MM</given-names></name></person-group>. <article-title>Substitutes for autologous bone graft in orthopaedic trauma</article-title>. <source>J Bone Joint Surg Br</source> <year>2001</year>; <volume>83</volume>(<issue>1</issue>): <fpage>3</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr8-0885328211415722"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neo</surname><given-names>M</given-names></name><name><surname>Herbst</surname><given-names>H</given-names></name><name><surname>Voigt</surname><given-names>CF</given-names></name><name><surname>Gross</surname><given-names>UM</given-names></name></person-group>. <article-title>Temporal and spatial patterns of osteoblast activation following implantation of beta-TCP particles into bone</article-title>. <source>J Biomed Mater Res</source> <year>1998</year>; <volume>39</volume>(<issue>1</issue>): <fpage>71</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr9-0885328211415722"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Doernberg</surname><given-names>MC</given-names></name><name><surname>von Rechenberg</surname><given-names>B</given-names></name><name><surname>Bohner</surname><given-names>M</given-names></name><name><surname>Grunenfelder</surname><given-names>S</given-names></name><name><surname>van Lenthe</surname><given-names>GH</given-names></name><name><surname>Muller</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>In vivo behavior of calcium phosphate scaffolds with four different pore sizes</article-title>. <source>Biomaterials</source> <year>2006</year>; <volume>27</volume>(<issue>30</issue>): <fpage>5186</fpage>–<lpage>5198</lpage>.</citation></ref>
<ref id="bibr10-0885328211415722"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pioletti</surname><given-names>DP</given-names></name><name><surname>Takei</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Van Landuyt</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>QJ</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name><etal/></person-group>. <article-title>The effects of calcium phosphate cement particles on osteoblast functions</article-title>. <source>Biomaterials</source> <year>2000</year>; <volume>21</volume>(<issue>11</issue>): <fpage>1103</fpage>–<lpage>1114</lpage>.</citation></ref>
<ref id="bibr11-0885328211415722"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arinzeh</surname><given-names>TL</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Mcalary</surname><given-names>J</given-names></name><name><surname>Daculsi</surname><given-names>G</given-names></name></person-group>. <article-title>A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation</article-title>. <source>Biomaterials</source> <year>2005</year>; <volume>26</volume>(<issue>17</issue>): <fpage>3631</fpage>–<lpage>3638</lpage>.</citation></ref>
<ref id="bibr12-0885328211415722"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LeGeros</surname><given-names>RZ</given-names></name></person-group>. <article-title>Calcium phosphate-based osteoinductive materials</article-title>. <source>Chem Rev</source> <year>2008</year>; <volume>108</volume>(<issue>11</issue>): <fpage>4742</fpage>–<lpage>4753</lpage>.</citation></ref>
<ref id="bibr13-0885328211415722"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>DE</given-names></name><name><surname>MacDonald</surname><given-names>BR</given-names></name><name><surname>Russell</surname><given-names>RG</given-names></name><name><surname>Gowen</surname><given-names>M</given-names></name></person-group>. <article-title>Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow</article-title>. <source>J Clin Invest</source> <year>1989</year>; <volume>83</volume>(<issue>6</issue>): <fpage>1930</fpage>–<lpage>1935</lpage>.</citation></ref>
<ref id="bibr14-0885328211415722"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Beek</surname><given-names>ER</given-names></name><name><surname>Cohen</surname><given-names>LH</given-names></name><name><surname>Leroy</surname><given-names>IM</given-names></name><name><surname>Ebetino</surname><given-names>FH</given-names></name><name><surname>Lowik</surname><given-names>CW</given-names></name><name><surname>Papapoulos</surname><given-names>SE</given-names></name></person-group>. <article-title>Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates</article-title>. <source>Bone</source> <year>2003</year>; <volume>33</volume>(<issue>5</issue>): <fpage>805</fpage>–<lpage>811</lpage>.</citation></ref>
<ref id="bibr15-0885328211415722"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heymann</surname><given-names>D</given-names></name><name><surname>Ory</surname><given-names>B</given-names></name><name><surname>Gouin</surname><given-names>F</given-names></name><name><surname>Green</surname><given-names>JR</given-names></name><name><surname>Redini</surname><given-names>F</given-names></name></person-group>. <article-title>Bisphosphonates: New therapeutic agents for the treatment of bone tumors</article-title>. <source>Trends Mol Med</source> <year>2004</year>; <volume>10</volume>(<issue>7</issue>): <fpage>337</fpage>–<lpage>343</lpage>.</citation></ref>
<ref id="bibr16-0885328211415722"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Udagawa</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders</article-title>. <source>Bone</source> <year>1995</year>; <volume>17</volume>(<issue>2</issue>): <fpage>137</fpage>–<lpage>144</lpage>.</citation></ref>
<ref id="bibr17-0885328211415722"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>MJ</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Benford</surname><given-names>HL</given-names></name><name><surname>Coxon</surname><given-names>FP</given-names></name><name><surname>Luckman</surname><given-names>SP</given-names></name><name><surname>Monkkonen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Cellular and molecular mechanisms of action of bisphosphonates</article-title>. <source>Cancer</source> <year>2000</year>; <volume>88</volume>(<issue>12</issue>): <fpage>2961</fpage>–<lpage>2978</lpage>.</citation></ref>
<ref id="bibr18-0885328211415722"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sohara</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Scadeng</surname><given-names>M</given-names></name><name><surname>Pollack</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate</article-title>. <source>Cancer Res</source> <year>2003</year>; <volume>63</volume>(<issue>12</issue>): <fpage>3026</fpage>–<lpage>3031</lpage>.</citation></ref>
<ref id="bibr19-0885328211415722"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>MR</given-names></name></person-group>. <article-title>Bisphosphonates and osteonecrosis of the jaw: Moving from the bedside to the bench</article-title>. <source>Cells Tissues Organs</source> <year>2009</year>; <volume>189</volume>(<issue>1–4</issue>): <fpage>289</fpage>–<lpage>294</lpage>.</citation></ref>
<ref id="bibr20-0885328211415722"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Astrand</surname><given-names>J</given-names></name><name><surname>Aspenberg</surname><given-names>P</given-names></name></person-group>. <article-title>Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening</article-title>. <source>J Orthop Res</source> <year>2004</year>; <volume>22</volume>(<issue>2</issue>): <fpage>244</fpage>–<lpage>249</lpage>.</citation></ref>
<ref id="bibr21-0885328211415722"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skoglund</surname><given-names>B</given-names></name><name><surname>Holmertz</surname><given-names>J</given-names></name><name><surname>Aspenberg</surname><given-names>P</given-names></name></person-group>. <article-title>Systemic and local ibandronate enhance screw fixation</article-title>. <source>J Orthop Res</source> <year>2004</year>; <volume>22</volume>(<issue>5</issue>): <fpage>1108</fpage>–<lpage>1113</lpage>.</citation></ref>
<ref id="bibr22-0885328211415722"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Bilston</surname><given-names>LE</given-names></name><name><surname>Little</surname><given-names>DG</given-names></name></person-group>. <article-title>A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair</article-title>. <source>J Orthop Res</source> <year>2005</year>; <volume>23</volume>(<issue>5</issue>): <fpage>1029</fpage>–<lpage>1034</lpage>.</citation></ref>
<ref id="bibr23-0885328211415722"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>N</given-names></name><name><surname>McDonald</surname><given-names>M</given-names></name><name><surname>Godfrey</surname><given-names>C</given-names></name><name><surname>Bilston</surname><given-names>L</given-names></name><name><surname>Little</surname><given-names>D</given-names></name></person-group>. <article-title>Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair</article-title>. <source>J Bone Miner Res</source> <year>2007</year>; <volume>22</volume>(<issue>6</issue>): <fpage>867</fpage>–<lpage>876</lpage>.</citation></ref>
<ref id="bibr24-0885328211415722"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>SH</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Back</surname><given-names>DA</given-names></name><name><surname>Alidoust</surname><given-names>M</given-names></name><name><surname>Schwabe</surname><given-names>P</given-names></name><name><surname>Haas</surname><given-names>NP</given-names></name><etal/></person-group>. <article-title>Local application of zoledronic acid incorporated in a poly(D,L-lactide) coated implant accelerates fracture healing in rats</article-title>. <source>Acta Orthop</source> <year>2008</year>; <volume>79</volume>(<issue>5</issue>): <fpage>717</fpage>–<lpage>725</lpage>.</citation></ref>
<ref id="bibr25-0885328211415722"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reinholz</surname><given-names>GG</given-names></name><name><surname>Getz</surname><given-names>B</given-names></name><name><surname>Pederson</surname><given-names>L</given-names></name><name><surname>Sanders</surname><given-names>ES</given-names></name><name><surname>Subramaniam</surname><given-names>M</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><etal/></person-group>. <article-title>Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts</article-title>. <source>Cancer Res</source> <year>2000</year>; <volume>60</volume>(<issue>21</issue>): <fpage>6001</fpage>–<lpage>6007</lpage>.</citation></ref>
<ref id="bibr26-0885328211415722"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viereck</surname><given-names>V</given-names></name><name><surname>Emons</surname><given-names>G</given-names></name><name><surname>Lauck</surname><given-names>V</given-names></name><name><surname>Frosch</surname><given-names>KH</given-names></name><name><surname>Blaschke</surname><given-names>S</given-names></name><name><surname>Grundker</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts</article-title>. <source>Biochem Biophys Res Commun</source> <year>2002</year>; <volume>291</volume>(<issue>3</issue>): <fpage>680</fpage>–<lpage>686</lpage>.</citation></ref>
<ref id="bibr27-0885328211415722"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panzavolta</surname><given-names>S</given-names></name><name><surname>Torricelli</surname><given-names>P</given-names></name><name><surname>Bracci</surname><given-names>B</given-names></name><name><surname>Fini</surname><given-names>M</given-names></name><name><surname>Bigi</surname><given-names>A</given-names></name></person-group>. <article-title>Alendronate and pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells</article-title>. <source>J Inorg Biochem</source> <year>2009</year>; <volume>103</volume>(<issue>1</issue>): <fpage>101</fpage>–<lpage>106</lpage>.</citation></ref>
<ref id="bibr28-0885328211415722"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Stemberger</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>NP</given-names></name><name><surname>Raschke</surname><given-names>M</given-names></name></person-group>. <article-title>Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors</article-title>. <source>J Biomed Mater Res, Appl Biomat</source> <year>2001</year>; <volume>58</volume>(<issue>4</issue>): <fpage>449</fpage>–<lpage>455</lpage>.</citation></ref>
<ref id="bibr29-0885328211415722"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Lubberstedt</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>NP</given-names></name><name><surname>Raschke</surname><given-names>M</given-names></name><name><surname>Schmidmaier</surname><given-names>G</given-names></name></person-group>. <article-title>IGF-I and TGF-beta 1 incorporated in a poly(d,l-lactide) implant coating maintain their activity over long-term storage-cell culture studies on primary human osteoblast-like cells</article-title>. <source>Biomaterials</source> <year>2004</year>; <volume>25</volume>(<issue>17</issue>): <fpage>3639</fpage>–<lpage>3644</lpage>.</citation></ref>
<ref id="bibr30-0885328211415722"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>S</given-names></name><name><surname>Kadow-Romacker</surname><given-names>A</given-names></name><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name></person-group>. <article-title>Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating</article-title>. <source>J Biomed Mater Res A</source> <year>2009</year>; <volume>91</volume>(<issue>1</issue>): <fpage>288</fpage>–<lpage>295</lpage>.</citation></ref>
<ref id="bibr31-0885328211415722"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Risteli</surname><given-names>L</given-names></name><name><surname>Risteli</surname><given-names>J</given-names></name></person-group>. <article-title>Biochemical markers of bone metabolism</article-title>. <source>Ann Med</source> <year>1993</year>; <volume>25</volume>(<issue>4</issue>): <fpage>385</fpage>–<lpage>393</lpage>.</citation></ref>
<ref id="bibr32-0885328211415722"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>M</given-names></name><name><surname>Overgaard</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Ongpipattanakul</surname><given-names>B</given-names></name><name><surname>Bunger</surname><given-names>C</given-names></name><name><surname>Soballe</surname><given-names>K</given-names></name></person-group>. <article-title>Transforming growth factor-beta stimulates bone ongrowth. Hydroxyapatite-coated implants studied in dogs</article-title>. <source>Acta Orthop Scand</source> <year>1996</year>; <volume>67</volume>(<issue>6</issue>): <fpage>611</fpage>–<lpage>616</lpage>.</citation></ref>
<ref id="bibr33-0885328211415722"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boanini</surname><given-names>E</given-names></name><name><surname>Torricelli</surname><given-names>P</given-names></name><name><surname>Gazzano</surname><given-names>M</given-names></name><name><surname>Giardino</surname><given-names>R</given-names></name><name><surname>Bigi</surname><given-names>A</given-names></name></person-group>. <article-title>Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells</article-title>. <source>Biomaterials</source> <year>2008</year>; <volume>29</volume>(<issue>7</issue>): <fpage>790</fpage>–<lpage>796</lpage>.</citation></ref>
<ref id="bibr34-0885328211415722"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kajiwara</surname><given-names>H</given-names></name><name><surname>Yamaza</surname><given-names>T</given-names></name><name><surname>Yoshinari</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Iyama</surname><given-names>S</given-names></name><name><surname>Atsuta</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats</article-title>. <source>Biomaterials</source> <year>2005</year>; <volume>26</volume>(<issue>6</issue>): <fpage>581</fpage>–<lpage>587</lpage>.</citation></ref>
<ref id="bibr35-0885328211415722"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valimaki</surname><given-names>VV</given-names></name><name><surname>Moritz</surname><given-names>N</given-names></name><name><surname>Yrjans</surname><given-names>JJ</given-names></name><name><surname>Vuorio</surname><given-names>E</given-names></name><name><surname>Aro</surname><given-names>HT</given-names></name></person-group>. <article-title>Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute</article-title>. <source>Bone</source> <year>2006</year> <volume>38</volume>: <fpage>432</fpage>–<lpage>443</lpage>.</citation></ref>
<ref id="bibr36-0885328211415722"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garbuz</surname><given-names>DS</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>WY</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Masri</surname><given-names>BA</given-names></name><name><surname>Oxland</surname><given-names>TR</given-names></name><etal/></person-group>. <article-title>Enhanced gap filling and osteoconduction associated with alendronate-calcium phosphate-coated porous tantalum</article-title>. <source>J Bone Joint Surg Am</source> <year>2008</year>; <volume>90</volume>(<issue>5</issue>): <fpage>1090</fpage>–<lpage>1100</lpage>.</citation></ref>
<ref id="bibr37-0885328211415722"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jakobsen</surname><given-names>T</given-names></name><name><surname>Baas</surname><given-names>J</given-names></name><name><surname>Kold</surname><given-names>S</given-names></name><name><surname>Bechtold</surname><given-names>JE</given-names></name><name><surname>Elmengaard</surname><given-names>B</given-names></name><name><surname>Soballe</surname><given-names>K</given-names></name></person-group>. <article-title>Local bisphosphonate treatment increases fixation of hydroxyapatite-coated implants inserted with bone compaction</article-title>. <source>J Orthop Res</source> <year>2009</year>; <volume>27</volume>(<issue>2</issue>): <fpage>189</fpage>–<lpage>194</lpage>.</citation></ref>
<ref id="bibr38-0885328211415722"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Lee</surname><given-names>HT</given-names></name><name><surname>Reinhardt</surname><given-names>RA</given-names></name><name><surname>Marky</surname><given-names>LA</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group>. <article-title>Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity</article-title>. <source>J Control Release</source> <year>2007</year>; <volume>122</volume>(<issue>1</issue>): <fpage>54</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr39-0885328211415722"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faucheux</surname><given-names>C</given-names></name><name><surname>Verron</surname><given-names>E</given-names></name><name><surname>Soueidan</surname><given-names>A</given-names></name><name><surname>Josse</surname><given-names>S</given-names></name><name><surname>Arshad</surname><given-names>MD</given-names></name><name><surname>Janvier</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro</article-title>. <source>J Biomed Mater Res A</source> <year>2009</year>; <volume>89</volume>(<issue>1</issue>): <fpage>46</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr40-0885328211415722"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>KA</given-names></name><name><surname>Jackson</surname><given-names>JK</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Chehroudi</surname><given-names>B</given-names></name><name><surname>Brunette</surname><given-names>DM</given-names></name><name><surname>Burt</surname><given-names>HM</given-names></name></person-group>. <article-title>Controlled release of alendronate from polymeric films</article-title>. <source>J Biomater Sci Polym Ed</source> <year>2009</year>; <volume>20</volume>(<issue>5–6</issue>): <fpage>653</fpage>–<lpage>672</lpage>.</citation></ref>
<ref id="bibr41-0885328211415722"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>S</given-names></name><name><surname>Kadow-Romacker</surname><given-names>A</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Schwabe</surname><given-names>P</given-names></name><name><surname>Schmidmaier</surname><given-names>G</given-names></name></person-group>. <article-title>Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro</article-title>. <source>J Biomed Mater Res A</source> <year>2007</year>; <volume>83</volume>(<issue>4</issue>): <fpage>1184</fpage>–<lpage>1191</lpage>.</citation></ref>
<ref id="bibr42-0885328211415722"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Schwabe</surname><given-names>P</given-names></name><name><surname>Strobel</surname><given-names>C</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name></person-group>. <article-title>Carrier systems and application of growth factors in orthopaedics</article-title>. <source>Injury</source> <year>2008</year>; <volume>39</volume>(<issue>2</issue>): <fpage>S37</fpage>–<lpage>S43</lpage>.</citation></ref>
<ref id="bibr43-0885328211415722"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Bail</surname><given-names>H</given-names></name><name><surname>Lucke</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>T</given-names></name><name><surname>Stemberger</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-β1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats</article-title>. <source>Bone</source> <year>2001</year>; <volume>28</volume>(<issue>4</issue>): <fpage>341</fpage>–<lpage>350</lpage>.</citation></ref>
<ref id="bibr44-0885328211415722"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greiner</surname><given-names>S</given-names></name><name><surname>Kadow-Romacker</surname><given-names>A</given-names></name><name><surname>Lubberstedt</surname><given-names>M</given-names></name><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name></person-group>. <article-title>The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro</article-title>. <source>J Biomed Mater Res A</source> <year>2007</year>; <volume>80</volume>(<issue>4</issue>): <fpage>769</fpage>–<lpage>775</lpage>.</citation></ref>
<ref id="bibr45-0885328211415722"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Lübberstedt</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>NP</given-names></name><name><surname>Raschke</surname><given-names>M</given-names></name></person-group>. <article-title>IGF-I and TGF-beta 1 incorporated in a poly(D,L-lactide) implant coating stimulates osteoblast differentiation and collagen-1 production but reduces osteoblast proliferation in cell culture</article-title>. <source>J Biomed Mater Res, Appl Biomat</source> <year>2003</year>; <volume>65b</volume>: <fpage>157</fpage>–<lpage>162</lpage>.</citation></ref>
<ref id="bibr46-0885328211415722"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Aoust</surname><given-names>P</given-names></name><name><surname>McCulloch</surname><given-names>CA</given-names></name><name><surname>Tenenbaum</surname><given-names>HC</given-names></name><name><surname>Lekic</surname><given-names>PC</given-names></name></person-group>. <article-title>Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria</article-title>. <source>Cell Tissue Res</source> <year>2000</year>; <volume>302</volume>(<issue>3</issue>): <fpage>353</fpage>–<lpage>363</lpage>.</citation></ref>
<ref id="bibr47-0885328211415722"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stadelmann</surname><given-names>VA</given-names></name><name><surname>Gauthier</surname><given-names>O</given-names></name><name><surname>Terrier</surname><given-names>A</given-names></name><name><surname>Bouler</surname><given-names>JM</given-names></name><name><surname>Pioletti</surname><given-names>DP</given-names></name></person-group>. <article-title>Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study</article-title>. <source>Eur Cell Mater</source> <year>2008</year>; <volume>16</volume>: <fpage>10</fpage>–<lpage>16</lpage>.</citation></ref>
<ref id="bibr48-0885328211415722"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Im</surname><given-names>GI</given-names></name><name><surname>Qureshi</surname><given-names>SA</given-names></name><name><surname>Kenney</surname><given-names>J</given-names></name><name><surname>Rubash</surname><given-names>HE</given-names></name><name><surname>Shanbhag</surname><given-names>AS</given-names></name></person-group>. <article-title>Osteoblast proliferation and maturation by bisphosphonates</article-title>. <source>Biomaterials</source> <year>2004</year>; <volume>25</volume>(<issue>18</issue>): <fpage>4105</fpage>–<lpage>4115</lpage>.</citation></ref>
<ref id="bibr49-0885328211415722"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>B</given-names></name><name><surname>To</surname><given-names>LB</given-names></name><name><surname>Farrugia</surname><given-names>AN</given-names></name><name><surname>Findlay</surname><given-names>DM</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Gronthos</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro</article-title>. <source>Bone</source> <year>2004</year>; <volume>34</volume>(<issue>1</issue>): <fpage>112</fpage>–<lpage>123</lpage>.</citation></ref>
<ref id="bibr50-0885328211415722"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orriss</surname><given-names>IR</given-names></name><name><surname>Key</surname><given-names>ML</given-names></name><name><surname>Colston</surname><given-names>KW</given-names></name><name><surname>Arnett</surname><given-names>TR</given-names></name></person-group>. <article-title>Inhibition of osteoblast function in vitro by aminobisphosphonates</article-title>. <source>J Cell Biochem</source> <year>2009</year>; <volume>106</volume>(<issue>1</issue>): <fpage>109</fpage>–<lpage>118</lpage>.</citation></ref>
<ref id="bibr51-0885328211415722"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>MJ</given-names></name><name><surname>Niehoff</surname><given-names>P</given-names></name><name><surname>Kimmig</surname><given-names>B</given-names></name><name><surname>Wiltfang</surname><given-names>J</given-names></name><name><surname>Acil</surname><given-names>Y</given-names></name></person-group>. <article-title>Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment</article-title>. <source>Clin Oral Investig</source> <year>2010</year>; <volume>14</volume>(<issue>1</issue>): <fpage>51</fpage>–<lpage>58</lpage>.</citation></ref>
<ref id="bibr52-0885328211415722"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Josse</surname><given-names>S</given-names></name><name><surname>Faucheux</surname><given-names>C</given-names></name><name><surname>Soueidan</surname><given-names>A</given-names></name><name><surname>Grimandi</surname><given-names>G</given-names></name><name><surname>Massiot</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Novel biomaterials for bisphosphonate delivery</article-title>. <source>Biomaterials</source> <year>2005</year>; <volume>26</volume>(<issue>14</issue>): <fpage>2073</fpage>–<lpage>2080</lpage>.</citation></ref>
<ref id="bibr53-0885328211415722"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teitelbaum</surname><given-names>SL</given-names></name></person-group>. <article-title>Bone resorption by osteoclasts</article-title>. <source>Science</source> <year>2000</year>; <volume>289</volume>(<issue>5484</issue>): <fpage>1504</fpage>–<lpage>1508</lpage>.</citation></ref>
<ref id="bibr54-0885328211415722"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>FP</given-names></name><name><surname>Merkel</surname><given-names>C</given-names></name><name><surname>Ziebart</surname><given-names>T</given-names></name><name><surname>Smeets</surname><given-names>R</given-names></name><name><surname>Walter</surname><given-names>C</given-names></name><name><surname>Al Nawas</surname><given-names>B</given-names></name></person-group>. <article-title>Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro</article-title>. <source>Clin Oral Investig</source> <year>2010</year>; <comment>[Epub ahead of print]</comment>.</citation></ref>
</ref-list>
</back>
</article>